Amotiv Limited (AOV) - Net Assets

Latest as of December 2025: CA$767.27 Million CAD ≈ $555.03 Million USD

Based on the latest financial reports, Amotiv Limited (AOV) has net assets worth CA$767.27 Million CAD (≈ $555.03 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$1.05 Billion ≈ $756.88 Million USD) and total liabilities (CA$279.03 Million ≈ $201.84 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how tangible is Amotiv Limited's equity to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets CA$767.27 Million
% of Total Assets 73.33%
Annual Growth Rate 4.38%
5-Year Change -8.88%
10-Year Change -21.68%
Growth Volatility 18.78

Amotiv Limited - Net Assets Trend (2014–2025)

This chart illustrates how Amotiv Limited's net assets have evolved over time, based on quarterly financial data. See how many days can Amotiv Limited fund operations to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Amotiv Limited (2014–2025)

The table below shows the annual net assets of Amotiv Limited from 2014 to 2025. For live valuation and market cap data, see Amotiv Limited (AOV) market capitalisation.

Year Net Assets Change
2025-12-31 CA$767.27 Million
≈ $555.03 Million
-3.50%
2024-12-31 CA$795.11 Million
≈ $575.17 Million
+6.46%
2023-12-31 CA$746.87 Million
≈ $540.28 Million
-9.56%
2022-12-31 CA$825.86 Million
≈ $597.41 Million
-1.92%
2021-12-31 CA$842.02 Million
≈ $609.10 Million
-4.99%
2020-12-31 CA$886.24 Million
≈ $641.09 Million
-3.15%
2019-12-31 CA$915.11 Million
≈ $661.97 Million
-11.16%
2018-12-31 CA$1.03 Billion
≈ $745.11 Million
+3.92%
2017-12-31 CA$991.21 Million
≈ $717.02 Million
+1.17%
2016-12-31 CA$979.72 Million
≈ $708.71 Million
+52.59%
2015-12-31 CA$642.06 Million
≈ $464.46 Million
+34.04%
2014-12-31 CA$478.99 Million
≈ $346.49 Million
--

Equity Component Analysis

This analysis shows how different components contribute to Amotiv Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 14894200000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Retained Earnings CA$148.94 Million 19.41%
Common Stock CA$530.14 Million 69.09%
Other Components CA$88.19 Million 11.49%
Total Equity CA$767.27 Million 100.00%

Amotiv Limited Competitors by Market Cap

The table below lists competitors of Amotiv Limited ranked by their market capitalization.

Company Market Cap
Gan Yuan Foods Co Ltd
SHE:002991
$576.85 Million
Shanghai National Center of Testing and Inspection for Electric Cable and Wire Co. Ltd.
SHE:301289
$576.97 Million
Wesure Global Tech Ltd
TA:WESR
$576.98 Million
Benakat Petroleum Energy
JK:BIPI
$577.16 Million
Sunny Loan Top Co Ltd
SHG:600830
$576.40 Million
Shenzhen Properties & Resources Development Group Ltd
SHE:000011
$576.02 Million
Shandong Binzhou Bohai Piston Co Ltd
SHG:600960
$575.83 Million
Sparebanken Møre
OL:MORG
$575.59 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Amotiv Limited's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 795,105,000 to 767,272,000, a change of -27,833,000 (-3.5%).
  • Net loss of 5,374,000 reduced equity.
  • Share repurchases of 6,352,000 reduced equity.
  • Other factors decreased equity by 16,107,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income CA$-5.37 Million -0.7%
Share Repurchases CA$6.35 Million -0.83%
Other Changes CA$-16.11 Million -2.1%
Total Change CA$- -3.50%

Book Value vs Market Value Analysis

This analysis compares Amotiv Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.20x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 532277201.64x to 1.20x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2013-12-31 CA$0.00 CA$9.29 x
2014-12-31 CA$8.36 CA$9.29 x
2015-12-31 CA$6.65 CA$9.29 x
2016-12-31 CA$8.08 CA$9.29 x
2017-12-31 CA$6.91 CA$9.29 x
2018-12-31 CA$7.19 CA$9.29 x
2019-12-31 CA$5.79 CA$9.29 x
2020-12-31 CA$6.71 CA$9.29 x
2021-12-31 CA$6.76 CA$9.29 x
2022-12-31 CA$7.19 CA$9.29 x
2023-12-31 CA$7.38 CA$9.29 x
2024-12-31 CA$7.95 CA$9.29 x
2025-12-31 CA$7.74 CA$9.29 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Amotiv Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -0.70%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -1.19%
  • • Asset Turnover: 0.43x
  • • Equity Multiplier: 1.36x
  • Recent ROE (-0.70%) is below the historical average (3.23%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2014 26.28% 34451.40% 0.00x 1.02x CA$77.96 Million
2015 5.32% 3294.79% 0.00x 1.01x CA$-30.04 Million
2016 1.89% 312.46% 0.01x 1.01x CA$-79.41 Million
2017 1.74% 199.72% 0.01x 1.01x CA$-81.88 Million
2018 2.34% 192.63% 0.01x 1.02x CA$-78.92 Million
2019 1.79% 30.59% 0.04x 1.61x CA$-66.56 Million
2020 3.58% 15.92% 0.19x 1.17x CA$-56.86 Million
2021 1.86% 6.44% 0.25x 1.18x CA$-68.53 Million
2022 -3.62% -10.18% 0.28x 1.28x CA$-112.48 Million
2023 -2.25% -5.13% 0.35x 1.27x CA$-91.52 Million
2024 0.54% 1.17% 0.39x 1.21x CA$-75.18 Million
2025 -0.70% -1.19% 0.43x 1.36x CA$-82.10 Million

Industry Comparison

This section compares Amotiv Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $704,417,929
  • Average return on equity (ROE) among peers: -63.29%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Amotiv Limited (AOV) CA$767.27 Million 26.28% 0.36x $576.83 Million
Aurora Cannabis Inc (ACB) $1.69 Million -10.52% 0.00x $171.89 Million
Aequus Pharmaceuticals Inc (AQS) $-6.45 Million 0.00% 0.00x $479.73K
Avicanna Inc (AVCN) $3.46 Million -426.03% 4.09x $12.28 Million
Avant Brands Inc (AVNT) $32.85 Million -68.65% 0.81x $6.98 Million
Bausch Health Companies Inc (BHC) $5.94 Billion 40.44% 5.31x $1.87 Billion
CanadaBis Capital Inc (CANB) $2.63 Million 23.10% 4.88x $1.53 Million
Cannabist Company Holdings Inc (CBST) $266.93 Million -39.33% 0.51x $12.41 Million
Cipher Pharmaceuticals Inc (CPH) $18.41 Million -56.20% 0.05x $297.74 Million
Cardiol Therapeutics Inc Class A (CRDL) $76.24 Million -32.43% 0.15x $118.76 Million

About Amotiv Limited

TO:AOV Canada Drug Manufacturers - Specialty & Generic
Market Cap
$681.27 Million
CA$941.78 Million CAD
Market Cap Rank
#11706 Global
#349 in Canada
Share Price
CA$9.29
Change (1 day)
-2.00%
52-Week Range
CA$5.75 - CA$9.48
All Time High
CA$10.90
About

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting;… Read more